MKI67 and pancreatic neuroendocrine tumor: Considering pancreatic NETs, with Ki-67 ≤10%, SSTR expression, and resectable “borderline” liver metastases, experts considered the following appropriate: (a) loco-regional therapy (eg, yttrium-90) followed by surgery (unanimity, 100%); (b) RLT followed by surgery if response (consensus, 81%); (c) chemotherapy followed by surgery if response (consensus, 77%).